Recently, Grit Biotechnology announced the completionSuper$60 millionSeries B financing.This round of financing was led by a fund under Shanghai CCI Investment Co., Ltd., with participation from Qianhai Ark, LIANDO, Yantai Yuanhe Equity Investment Fund Management Co., Ltd., He Fangtian Partnership Enterprise, as well as existing investors Sherpa Healthcare Partners, Decheng Capital, and Matrix Partners China.This financing will supportGrit GrowthThingThe development of the Tumor-Infiltrating Lymphocyte (TIL) pipeline, including the pivotal Phase II trial of GT101 and the development of next-generation gene-edited TIL products.Grit LifeThingFounded in 2019, it is a leading cell therapy company focused on providing transformative cancer treatments. GT101 is currently the fastest-developing TIL therapy in China and will enter Phase 2 trials by the end of 2023.Gravel BornThingThere are four core technology platforms, which are the core of TIL development: StemTexp®Dry TIL Expansion Technology, StaViral® Stable Production Cell Line, KOReTIL® High-efficiency TIL Gene Knockout System and FullGenomic CRISPR/Cas9 Screening Platform ImmuT Finder® Immune Modulation Target Discovery Platform. These platforms enable the development of next-generation gene-edited TIL products.GT201 isGravel BornThingA gene-engineered TIL product that enhances T-cell survival and function by expressing a key membrane-bound cytokine. It surpasses conventional TIL therapy in proliferation, tumor killing, and persistence, reducing reliance on IL-2. Currently in Phase 1 clinical trials.GT316 is the next-generation TIL product that enhances the performance of TIL by knocking out immune-modulating targets identified through ImmuT Finder® CRISPR/Cas9 screening. In PDX mouse models, GT316 effectively eliminated tumors supported by low-dose IL-2 with minimal toxicity. Compared to traditional TIL products, it offers significant clinical benefits and is currently undergoing IIT clinical trials in China.Follow the official account below to explore the world with us!
